Topical Everolimus in Patients With Tuberous Sclerosis Complex
Key facts
- Who runs it
- Hospices Civils de Lyon
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2/3
- Started
- Dec 2020
- Ended
- Dec 2024
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Everolimus
- Placebo
- Record updated
- 3 May 2021
- Why it stopped
- Pharmaceutical and financial difficulties
Who can take part
- Age
- 0 years to 2 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Patients over the age of 2 years
- With definite or possible diagnosis of TSC
- With at least 3 FA, diagnosed by a dermatologist
- Patients (or parents or legal guardians) who have provided written informed consent prior to participation in the study
- Willing and able to comply with study requirements
- With negative blood pregnancy test at the screening visit and using effective contraceptive methods for women of childbearing potential, up to 12 weeks after treatment discontinuation
- Covered by national health insurance
Who cannot take part
- Systemic treatment by sirolimus, everolimus, or any other immunosuppressive drug, during the previous 6 months
- Use of topical tacrolimus or sirolimus on the face, during the previous 6 months
- Destructive treatment (laser therapy, surgery, cryotherapy) of facial angiofibromas during the previous 6 months
- Concomitant use of topical treatments that could affect facial erythema (e.g. Brimonidine)
- Known internal organ involvement requiring systemic mTOR inhibitor in the next 6 months
- Immunosuppression (immunosuppressive disease or immunosuppressive treatment)
- Known chronic infectious disease Known hypersensitivity to mTOR inhibitor
- Chronic renal insufficiency (estimated Glomerular Filtration Rate < 60 mls/min)
- Uncontrolled diabetes
- Chronic liver disease (SGOT or SGPT > 3 times upper normal limit)
- Brest feeding or pregnant women, or women on childbearing age without any effective method of contraception during treatment and up to 12 weeks after treatment discontinuation
- Neutropenia < 1000/mm3
- Thrombopenia < 75,000/mm3
- Uncontrolled dyslipidaemia
- Subjects who, in the Investigator's opinion, are unable or unwilling to comply with the protocol
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Tuberous sclerosis complex (TSC) is a rare genetic multisystem disorder characterized by the development of hamartomas in several organs (e.g. brain, heart, kidney, liver, lung), and skin in more than 90% of cases. Facial angiofibromas (FA), present in about 80% of patients, are a stigmatizing hallmark of the disease. Everolimus could be a candidate for use as a topical formulation to treat FA. This adaptive seamless Phase II/III study primary objective is to determine the dose of topical everolimus for treatment of FA and evaluate the efficacy and safety of topical everolimus versus placebo in patients with angiofibromas.
The 4 groups in the trial
- Topical everolimus 0.1%Treatment being tested
Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
Treatment: Everolimus
- Topical everolimus 0.5%Treatment being tested
Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
Treatment: Everolimus
- Topical everolimus 1%Treatment being tested
Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
Treatment: Everolimus
- Topical placeboPlacebo, for comparison
Topical placebo will be identical to the everolimus topical formulation. Topical placebo will be applied to the affected areas, once daily, in the evening, for 6 months by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Topical Everolimus Versus Placebo for the Treatment of Facial Angiofibromas in Patients With Tuberous Sclerosis Complex. A Phase II/III, Multicentre, Randomized, Double-blind, Placebo-controlled Study of 3 Doses of Topical Everolimus.
- Record updated
- 3 May 2021